Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2020

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Get ahead with in-depth pharmaceutical competitive intelligence

Stay on top of the rapidly changing competitive landscape with detailed insight and intelligence on key industry, commercial, clinical, regulatory, and R&D events.

Master the marketplace

To succeed in the pharmaceutical marketplace, it’s vital to stay up to date with developments that can affect your business. Our competitive and market intelligence can give you all the credible, detailed information you need in one place.

What we offer

You can quickly access referenced information across global key industry developments in the pharmaceutical and medical technology markets with our easy-to-use solutions and expert analysts.

Build detailed competitive and market landscape analyses quickly, with access to global information on:

Drug and device development
Patient populations
Clinical trials
Drug and device patents
Market moving events
Patient-based sales forecasts

How it helps

We help you more accurately:

Prioritize pharmaceutical R&D spend by finding gaps and unmet needs through the analysis of competitors’ targets and R&D priorities
Understand disease epidemiology and disease sub-populations targeted in clinical development
Anticipate market changes through patent expiration tracking
Earmark who is entering or exiting your market via licensing or acquisition, as well as who is securing or providing funding
Project revenue for your pipeline and marketed drugs

Relevant products

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

Prioritize market opportunities
Identify unmet needs
Make informed decisions

Scrip: industry news and insights

Key benefits:

Follow market developments
Go beyond the news
Hear from news makers

Biomedtracker: follow the drug development process

Track and assess key events that will impact a drug’s probability of technical success and approval.

Key benefits:

Stay up to date
Get ahead of the competition
Conference coverage

View all content

Scrip

J.P. Morgan Conference Updates

By Mandy Jackson 17 Jan 2020

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

View article
Scrip

O’Day Lays Out Plan For Gilead’s Continued HIV Dominance

By Joseph Haas 15 Jan 2020

Biktarvy’s powerful sales growth and the potential of a first-in-class capsid inhibitor in both prevention and heavily treatment-experienced patients are key to Gilead’s plan for staying on top in HIV.

View analysis
Scrip

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

By Jung Won Shin 15 Jan 2020

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic Clinical Trials Deal trends

View analysis
Scrip

Scrip Asks...What Does 2020 Hold For Biopharma? Part 1: Therapeutic Advances

By Eleanor Malone 08 Jan 2020

Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.

View analysis
Scrip

J.P. Morgan 2020: What To Watch For At The Industry's Biggest Meeting

By Jessica Merrill 08 Jan 2020

The J.P. Morgan Healthcare conference is being held a week later than usual, which only makes us more ready to hear what the industry's leaders have in store. Here's a preview of potential hot topics.

View analysis
Scrip

Scrip Asia 100 Report Extract

18 Dec 2019

Access Asia Pharma Intelligence expertise and hear from Pharma journalists across Asia to reveal deep regional expertise with this sample of Scrip's Asia 100 Report.

Single report
Scrip

Podcast: Significant Approvals, Diabetes and NASH In India, Japan M&A

By Brian Yang 18 Dec 2019

Join the Asia-based content team for Scrip and the Pink Sheet for their first podcast as they take a look at some of the most significant regional pharma stories of the past few weeks.

Topic Drug approval Business Strategies

Full podcast
Scrip

Alnylam Seeking Lumasiran Approvals Soon, But Has Two Rivals On Its Heels

By Mandy Jackson 18 Dec 2019

Phase III results support early 2020 filings for what could be the RNAi specialist’s third commercial product, but two competing drugs for primary hyperoxaluria from Dicerna and OxThera aren’t far behind.

View article
Scrip

Seven Talking Points At ASH 2019

By Andrew McConaghie 16 Dec 2019

The tireless pace of change in hemato-oncology was showcased in Orlando.

Topic Cancer Clinical Trials

View article
Scrip

Sanofi's €10bn Dupixent Plan: 'We're Going To Put The JAKs Properly In Their Place'

By Jessica Merrill 16 Dec 2019

Sanofi's new CEO has ambitious forecasts for Dupixent in atopic dermatitis, asthma and other indications. The French pharma outlined how it plans to reach that goal despite new competition vying to get in.

View article
Scrip

Pharma Finds Its Way in AI

By Leah Samuel 06 Dec 2019

Early adopters of artificial intelligence are discovering how best to use it. Some of them are sharing lessons they have learned.

View analysis
Scrip

More Top Level Pharma Exits In India As Cipla COO Departs

By Anju Ghangurde 06 Dec 2019

Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.

View article
Scrip

Novartis Sees Reimbursement Advantage For PCSK9 Launch

By Jessica Merrill 28 Nov 2019

Administration under the medical benefit/Medicare Part B could mean easier reimbursement. The company outlined early plans for the launch of inclisiran after announcing it will buy The Medicines Company for $9.7bn.

Topic Business Strategies Deal trends Reimbursement

View analysis
Scrip

Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval

By Andrew McConaghie 28 Nov 2019

John Thero insists company is focused on approval and launch, as interest in European rights grow.

View article
Trialtrove

Trialtrove 2018 Clinical Trials Roundup Surveying the Landscape of 2018 Trial Starts infographic

21 Nov 2019

A clear view of the past is often the surest way to plan for the future. The annual analysis of Phase I-III clinical trials from Citeline’s Trialtrove reveals the priorities and strategies of the biopharma industry. This infographic lets you clearly see the players, trials, and trends.

Topic Drug Development Landscape BioPharmaceutical Business Strategies

View article